|Articles|August 22, 2022

Figures for Serotonin: A Biography

These are the extra figures for John J. Miller, MD's article, "Serotonin: A Biography" from the 2022 September issue.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

ByLeah Kuntz,Tri Doan, MD, PhD

July 20th 2026

GABA Deficits and Sleep Disruption in Early Alzheimer Disease

ByKsenia Kastanenka, PhD

June 15th 2026

Monoamines: A Full House

ByJohn J. Miller, MD

June 10th 2026

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

ByKim Do, PhD,Jessica Walters

June 3rd 2026

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

ByWilliam Li, MD,Morgan Hardy, MD

June 2nd 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Video

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Video

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

Video

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Figures for Serotonin: A Biography

Related Content

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

GABA Deficits and Sleep Disruption in Early Alzheimer Disease

Monoamines: A Full House

Insights Into Mechanism-Based Biomarkers for Psychosis Prediction from Kim Do, PhD

Nonpharmacological Augmentation of Ketamine, Neuroplasticity, and Behavioral Therapy

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

Remlifanserin for the Treatment of Alzheimer Disease Psychosis Receives FDA Fast Track Designation

Future DSM Plans Overlook Core Problem of Validity

Targeting APOE4: A Promising Therapeutic Strategy for Alzheimer Disease

Assessing Antipsychotics as Antidepressant Adjuncts

Bipolar Disorder in Women of Childbearing Age: Proper Treatment Before Pregnancy